Latest news
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - simplywall.stsimplywall.st · Sun, 09 Aug 2026 08:35:41 GMTDyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingViewTradingView · Thu, 06 Aug 2026 23:21:02 GMTFMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - Stock TitanStock Titan · Thu, 06 Aug 2026 14:21:56 GMTHow FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story - simplywall.stsimplywall.st · Mon, 03 Aug 2026 20:53:00 GMTMorgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45 - MoomooMoomoo · Fri, 31 Jul 2026 13:31:00 GMTDyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeatMarketBeat · Fri, 31 Jul 2026 10:14:41 GMTRBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative Risk - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMTDyne Therapeutics, Inc. Stock 12‑Month Price Target Raised to $39.53, Implies 58% Upside - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMT